comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 03:32:13 - browse：76555

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The release of Novo Nordisk’s latest earnings report on Thursday provided a chance for executives to tout their major win this week — outcomes from a large trial showing the company’s obesity drug Wegovy cut the risk of heart complications by 20%.

But once again, much of the attention was focused on the company’s struggles to meet what Novo CEO Lars Fruergaard Jørgensen referred to as the “overwhelming demand for Wegovy.”

Jørgensen reiterated that the company was racing to expand supply and had brought on more contract manufacturing support, but Novo said Thursday that the company would continue to restrict the availability of lower-strength starter doses in the United States to ensure that patients on the drug would not have their medication interrupted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Prosthetic arm enables patients to feel the objects they grip

hotspot

leisure time

WSS

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

What will save rural psychiatry services? Higher Medicaid payments

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Akili, maker of video game for ADHD, to be acquired for 34 million

Wikipedia

comprehensive

hotspot

Heart attack and stroke risk calculators need revising

Insmed lung disease drug hits target in key Phase 3 trial

Drug repurposing or repositioning? The language matters

Report: NIH

In age of alternative facts, a scholarly course on calling out crap

Biohaven protein

Alkermes shareholders re

Focused ultrasound for uterine fibroids: an uphill battle

Wildfire smoke exposes gaps in outdoor worker protections

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

focus

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Scientists successfully use ultrasound imaging to map brain activity

First Opinion Podcast: What happens when kids become caregivers?

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Report: NIH

Biohaven protein

leisure time

hotspot

focus

hotspot